Astra, HEC Settle Patent Lawsuit on Brilinta Blood-Thinner

AstraZeneca had claimed HEC Pharm’s generic version of Brilinta, used to treat heart disease, infringes two of Astra’s patents.

• HEC is blocked from selling its copycat until the patents have expired, “unless otherwise specifically authorized” in the confidential settlement, according to agreement approved Monday in federal court in Newark, New Jersey
• Patents expire in July 2021 and October 2024: FDA Orange Book
• Brilinta had U.S. sales of $500 million during the first nine months of 2019, 22% higher than during the same period a year earlier, Astra said Oct. 24 in its quarterly earnings report
• Astra sued Dr. Reddy’s ...